First International Conference of American States

Aerami Therapeutics Announces Pharmacokinetic Data Demonstrating the Potential of AER-901 (Inhaled Imatinib) to Achieve Therapeutic Levels at Low Inhaled Doses for Treatment of Pulmonary Hypertension

Retrieved on: 
Wednesday, May 24, 2023
PK, Rat, PAH, Safety, ATS, Survival, Clinical trial, ILD, Woman, Pulmonary hypertension, Cough, Lung, Investigational New Drug, American Thoracic Society, First International Conference of American States, Patient, Orthostatic hypertension, FDA, IND, Conference, Pharmaceutical industry

In addition, preliminary safety findings from the completed AER-901 Phase 1 clinical trial (NCT04903730) were presented.

Key Points: 
  • In addition, preliminary safety findings from the completed AER-901 Phase 1 clinical trial (NCT04903730) were presented.
  • AER-901 is in development to address critical unmet medical need for people with two serious and rare forms of pulmonary hypertension – PAH and PH-ILD.
  • Pulmonary hypertension is a serious complication of ILD for more than 80,000 people in the U.S. and Europe.
  • Full results for the Phase 1 study in healthy volunteers will be presented at a future meeting.